Africa’s EVA Pharma, France’s DNA Script, and Belgium’s Quantoom Biosciences have signed a Memorandum of Understanding which aims to develop the first-ever digital-to-biologics, end-to-end mRNA production platform, focusing on nucleic acid-based vaccines and therapeutics, including mRNA and saRNA vaccines for both human and animal health. The platform will integrate DNA Script’s enzymatic DNA synthesis technologies with Quantoom’s Ntensify mRNA synthesis and Ncapsulate formulation technologie...